Lopinavir/ritonavir did not shorten the duration of SARS CoV-2 shedding in patients with mild pneumonia in Taiwan

Chien-Yu Cheng; Yu-Lin Lee; Cheng-Pin Chen; Yi-Chun Lin; Chun-Eng Liu; Chia-Hung Liao; Shu-Hsing Cheng

doi:10.1016/j.jmii.2020.03.032

Lopinavir/ritonavir did not shorten the duration of SARS CoV-2 shedding in patients with mild pneumonia in Taiwan

J Microbiol Immunol Infect. 2020 Jun;53(3):488-492. doi: 10.1016/j.jmii.2020.03.032. Epub 2020 Apr 3.

Authors

Chien-Yu Cheng¹, Yu-Lin Lee², Cheng-Pin Chen³, Yi-Chun Lin⁴, Chun-Eng Liu⁵, Chia-Hung Liao⁶, Shu-Hsing Cheng⁷

Affiliations

¹ Division of Infectious Diseases, Department of Internal Medicine, Taoyuan General Hospital, Ministry of Health and Welfare, Taoyuan, Taiwan; School of Public Health, National Yang-Ming University, Taipei, Taiwan. Electronic address: [email protected].
² Department of Internal Medicine, Changhua Christian Hospital, Taiwan. Electronic address: [email protected].
³ Division of Infectious Diseases, Department of Internal Medicine, Taoyuan General Hospital, Ministry of Health and Welfare, Taoyuan, Taiwan; Institute of Clinical Medicine, National Yang-Ming University, Taipei, Taiwan.
⁴ Division of Infectious Diseases, Department of Internal Medicine, Taoyuan General Hospital, Ministry of Health and Welfare, Taoyuan, Taiwan.
⁵ Department of Internal Medicine, Changhua Christian Hospital, Taiwan.
⁶ Department of Internal Medicine, Nantou Hospital, Ministry of Health and Welfare, Taoyuan, Taiwan.
⁷ Division of Infectious Diseases, Department of Internal Medicine, Taoyuan General Hospital, Ministry of Health and Welfare, Taoyuan, Taiwan; School of Public Health, Taipei Medical University, Taipei, Taiwan. Electronic address: [email protected].

Abstract

An increase of Ct values was 0.9 per day in 2 cases of COVID-19 treated with lopinavir/ritonavir (LPV/r), an increase was 1.0 per day in 3 cases without LPV/r through illness day 1-10, indicating that LPV/r did not shorten the duration of SARS CoV-2 shedding.

Keywords: COVID-19; Lopinavir/ritonavir (LPV/r); SARS CoV-2; Shedding.

Publication types

Case Reports

MeSH terms

Antiviral Agents / therapeutic use*
Betacoronavirus / drug effects*
COVID-19
Chloroquine / therapeutic use
Coronavirus Infections / drug therapy*
Coronavirus Infections / pathology*
Drug Combinations
Female
Humans
Lopinavir / therapeutic use*
Male
Middle Aged
Pandemics
Pneumonia, Viral / drug therapy*
Pneumonia, Viral / pathology*
Ribavirin / therapeutic use
Ritonavir / therapeutic use*
SARS-CoV-2
Taiwan
Virus Shedding / drug effects*

Substances

Antiviral Agents
Drug Combinations
lopinavir-ritonavir drug combination
Lopinavir
Ribavirin
Chloroquine
Ritonavir